TNSN07202A1 - Derives d'acide 7-(2h-pyrazole-3-yl)-3, 5-dihyroxy heptanoique servant d'inhibiteurs de hmg-co a reductase pour le traitement de la lipidemie - Google Patents

Derives d'acide 7-(2h-pyrazole-3-yl)-3, 5-dihyroxy heptanoique servant d'inhibiteurs de hmg-co a reductase pour le traitement de la lipidemie

Info

Publication number
TNSN07202A1
TNSN07202A1 TNP2007000202A TNSN07202A TNSN07202A1 TN SN07202 A1 TNSN07202 A1 TN SN07202A1 TN P2007000202 A TNP2007000202 A TN P2007000202A TN SN07202 A TNSN07202 A TN SN07202A TN SN07202 A1 TNSN07202 A1 TN SN07202A1
Authority
TN
Tunisia
Prior art keywords
cycloalkyl
specifically
heteroaryl
alkyl
aryl
Prior art date
Application number
TNP2007000202A
Other languages
English (en)
Inventor
Chulho Choi
Richard H Hutchings
Jeffrey A Pfefferkorn
Daniel Meritt Bowles
William Keun Chan Park
Original Assignee
Warner Lambert Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=35708411&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=TNSN07202(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Warner Lambert Co filed Critical Warner Lambert Co
Publication of TNSN07202A1 publication Critical patent/TNSN07202A1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
    • C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D231/12—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
    • C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D231/14—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/06—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Diabetes (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Hematology (AREA)
  • Rheumatology (AREA)
  • Neurosurgery (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Obesity (AREA)
  • Biomedical Technology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Neurology (AREA)
  • Vascular Medicine (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Steroid Compounds (AREA)

Abstract

La présente invention propose des composés de formules (I), (IV) et (V) et des intermédiaires de formules (VI) et (VII) : (I), (IV), (V), (VI), (VII), formules dans lesquelles : R1 représente un atome d'hydrogène, un atome d'halogène, un groupe alkyle en C1 à C7, cycloalkyle en C3 à C8, aryle, aralkyle, hétéroaryle ou hétéroaralkyle ; plus spécifiquement, R1 représente un groupe alkyle en C1 à C7 ou cycloalkyle en C3 à C8 ; encore plus spécifiquement, R1 représente un groupe isopropyle ; le groupe alkyle cycloalkyle, aryle aralkyle, hétéroaryle ou hétéroaralkyle de R1 étant facultativement substitué ; R2 représente un atome d'hydrogène, un atome d'halogène, un groupe alkyle en C1 à C7, cycloalkyle en C3 à C8, aryle aralkyle, hétéroaryle, hétéroaralkyle, NC-, R2bR2aNCO(CH2)n -, R2bR2aNS(O)n -, R2cS(O)n-, R2bR2aN(CH2)n -, R2b-J-C(O)NR2a(CH2)n -, R2b-J-SO2NR2a(CH2)n -, R2b-J-SONR2a(CH2)n, R7OOC(CH2)n – ou R7CO(CH2)n - ; plus spécifiquement, R2 représente un groupe R2bR2a NCO(CH2)n - ; encore plus spécifiquement, R2 représente un groupe R2bR2aNCO- ; le groupe alkyle, cycloalkyle, hétéroaryle ou hétéroaralkyle de R2 étant facultativement substitué ; R3 représente un atome d'hydrogène, un groupe alkyle en C1 à C6, cycloalkyle en C3 à C6, aryle, aralkyle, hétéroaryle ou hétéroaralkyle ; plus spécifiquement R3 représente un groupe aryle ; encore plus spécifiquement, R3 représente un groupe phényle ou p-fluorophényle ; le groupe alkyle, cycloalkyle, aryle aralkyle, hétéroaryle ou hétéroaralkyle de R3 étant facultativement substitué et représentant une liaison ou étant absent. Les autres substituants sont définis dans les revendications. La présente invention concerne des composés et compositions pharmaceutiques utiles comme agents hypocholestérolémiques et hypolipidémiques. Plus spécifiquement, la présente invention concerne certains puissants inhibiteurs de l'enzyme 3-hydroxy-3-méthylglutaryl-coenzyme-A-réductase (« HMG-CoA-réductase »). Les composés sont utiles pour le traitement de l'hyperlipidémie, l'hypercholestérolémie, de l'hypertriglycéridémie, de l'athérosclérose, de la maladie d'Alzheimer, de l'hypertrophie prostatique bénigne (BPH) du diabète et de l'ostéoporose.
TNP2007000202A 2004-11-23 2007-05-22 Derives d'acide 7-(2h-pyrazole-3-yl)-3, 5-dihyroxy heptanoique servant d'inhibiteurs de hmg-co a reductase pour le traitement de la lipidemie TNSN07202A1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US63048104P 2004-11-23 2004-11-23
PCT/IB2005/003461 WO2006056845A1 (fr) 2004-11-23 2005-11-14 Derives d'acide 7-(2h-pyrazol-3-yl)-3, 5-dihyroxy-heptanoique comme inhibiteurs de hmg co-a reductase pour le traitement de l'hyperlipidemie

Publications (1)

Publication Number Publication Date
TNSN07202A1 true TNSN07202A1 (fr) 2008-11-21

Family

ID=35708411

Family Applications (1)

Application Number Title Priority Date Filing Date
TNP2007000202A TNSN07202A1 (fr) 2004-11-23 2007-05-22 Derives d'acide 7-(2h-pyrazole-3-yl)-3, 5-dihyroxy heptanoique servant d'inhibiteurs de hmg-co a reductase pour le traitement de la lipidemie

Country Status (25)

Country Link
US (2) US7446121B2 (fr)
EP (1) EP1819681B1 (fr)
JP (1) JP2008520642A (fr)
KR (1) KR20070084455A (fr)
AP (1) AP2007003979A0 (fr)
AR (1) AR052244A1 (fr)
AT (1) ATE439347T1 (fr)
AU (1) AU2005308575A1 (fr)
BR (1) BRPI0518300A2 (fr)
CA (1) CA2590533C (fr)
CR (1) CR9102A (fr)
DE (1) DE602005016009D1 (fr)
EA (1) EA200700875A1 (fr)
ES (1) ES2328384T3 (fr)
GT (1) GT200500338A (fr)
IL (1) IL182569A0 (fr)
MA (1) MA30108B1 (fr)
MX (1) MX2007005137A (fr)
NL (1) NL1030487C2 (fr)
PA (1) PA8653401A1 (fr)
PE (1) PE20061057A1 (fr)
TN (1) TNSN07202A1 (fr)
TW (1) TW200626556A (fr)
UY (1) UY29220A1 (fr)
WO (1) WO2006056845A1 (fr)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AP2007003979A0 (en) * 2004-11-23 2007-06-30 Warner Lambert Co 7-(2h-pyrazol-3-yl)-3,5-dihyroxy-heptanoic acid derivatives as hmg co-a reductase inhibitors for thetreatment of lipidemia
WO2006087630A2 (fr) * 2005-02-16 2006-08-24 Warner-Lambert Company Llc Inhibiteurs oxypyrazole de l'enzyme hmg co-a reductase
WO2007107843A1 (fr) * 2006-03-22 2007-09-27 Pfizer Products Inc. Procédés de traitement avec des inhibiteurs de la cetp
US7834050B2 (en) 2006-03-29 2010-11-16 Duke University Small molecule insulin mimetics absent quinones
WO2008059372A2 (fr) * 2006-11-17 2008-05-22 Pfizer Products Inc. Forme cristalline d'un sel de sodium de l'acide (3r,5r)-7-[2-(4-fluoro-phényl)-4-isopropyl-5-(4-méthyl-benzylcarbamoyl)-2h-pyrazol-3-yl]-3,5-dihydroxy-heptanoïque
EP2630135B1 (fr) * 2010-10-21 2020-03-04 Bayer Intellectual Property GmbH 1-(carbonyl hétérocyclique)pipéridines
AR087701A1 (es) * 2011-08-31 2014-04-09 Japan Tobacco Inc Derivados de pirazol con actividad inhibidora de sglt1
CA2856196C (fr) 2011-12-06 2020-09-01 Masco Corporation Of Indiana Distribution d'ozone dans un robinet
WO2017112795A1 (fr) 2015-12-21 2017-06-29 Delta Faucet Company Système de distribution de fluide comprenant un dispositif désinfectant
EP3778593A4 (fr) * 2018-04-04 2021-12-22 Japan Tobacco Inc. Composé de pyrazole substitué par hétéroaryle et son utilisation médicinale
CN114425329B (zh) * 2022-03-10 2024-04-19 西安凯立新材料股份有限公司 孕烯醇酮醋酸酯合成用催化剂及其制备方法和应用
US12274680B2 (en) 2022-09-13 2025-04-15 II George William Creasy Treatment of benign prostatic hypertrophy with capsinoids

Family Cites Families (103)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE1154810B (de) * 1961-04-01 1963-09-26 Knoll Ag Verfahren zur Herstellung basisch substituierter Phenylacetonitrile
US3262977A (en) * 1962-03-10 1966-07-26 Chinoin Gyogyszer Es Vegyeszet N-aralkyl-1, 1-diphenyl-propylamine derivatives
BE637389A (fr) * 1962-09-13
US3857952A (en) * 1967-12-22 1974-12-31 May & Baker Ltd Certain benzene derivatives useful in treating cardiac disorders
CH507249A (de) * 1968-05-31 1971-05-15 Sandoz Ag Verfahren zur Herstellung von 2-Brom-a-ergokryptin
US3822287A (en) * 1969-04-17 1974-07-02 Rexall Drug Chemical Process for preparation of substituted 3,4-(diphenyl)chromans
US3683080A (en) * 1970-08-28 1972-08-08 Procter & Gamble Compositions for inhibiting anomalous deposition and mobilization of calcium phosphate in animal tissue
BE795735A (fr) * 1972-03-06 1973-06-18 Cerm Cent Europ Rech Mauvernay Nouvelles ethylenediamines substituees a activite cardiovasculaire
GB1435139A (en) * 1972-08-17 1976-05-12 Sumitomo Chemical Co Thiazole derivatives
US4062950A (en) * 1973-09-22 1977-12-13 Bayer Aktiengesellschaft Amino sugar derivatives
US4133814A (en) * 1975-10-28 1979-01-09 Eli Lilly And Company 2-Phenyl-3-aroylbenzothiophenes useful as antifertility agents
JPS608117B2 (ja) * 1977-02-08 1985-02-28 財団法人微生物化学研究会 新生理活性物質エステラスチンおよびその製造法
DE2719912C3 (de) * 1977-05-04 1979-12-06 Bayer Ag, 5090 Leverkusen Verfahren zur Isolierung von 0- |4,6-Dideoxy-4- [JJl S-O,4,6/5)-4,5,6-trihydroxy-3-hydroxymethyl-2cyclohexen-1-yl] -amino] - a -D-glucopyranosyl} -(I Pfeil nach rechts 4)-0- a D-glucopyranosyl-(l Pfeil nach rechts 4)-D-glucopyranose aus Kulturbrühen
DE2733747C2 (de) * 1977-07-27 1979-09-27 Hoechst Ag, 6000 Frankfurt Verfahren zur Herstellung von 2,2 Dichlorhydrazobenzol
DE2860900D1 (en) * 1977-08-22 1981-11-05 Ici Plc Triphenylalkene derivatives, process for their preparation and pharmaceutical compositions containing them
NO154918C (no) * 1977-08-27 1987-01-14 Bayer Ag Analogifremgangsmaate til fremstilling av terapeutisk aktive derivater av 3,4,5-trihydroksypiperidin.
CA1147342A (fr) * 1977-10-12 1983-05-31 Kazuo Imai Procede de preparation de nouveaux derives de la phenylethanolamine
JPS5953920B2 (ja) * 1977-12-28 1984-12-27 東洋醸造株式会社 新規なアミノ糖化合物およびその製法
CA1121290A (fr) * 1978-02-14 1982-04-06 Yasuji Suhara Derives amines d'un sucre
JPS559058A (en) * 1978-07-06 1980-01-22 Dainippon Pharmaceut Co Ltd 1-(3-mercapto-2-methylpropanoyl)prolyl amino acid derivative
DE2928485A1 (de) * 1979-07-14 1981-01-29 Bayer Ag Verwendung von harnstoffderivaten als arzneimittel bei der behandlung von fettstoffwechselstoerungen
ES8207217A1 (es) * 1980-10-09 1982-09-01 Hoechst Ag Procedimiento para la preparacion de un inactivador de alfa-amilasa
EP0056194B1 (fr) * 1981-01-05 1984-09-12 Takeda Chemical Industries, Ltd. Pseudo-aminosucres N-substitués, leur préparation et leur utilisation
US4418068A (en) * 1981-04-03 1983-11-29 Eli Lilly And Company Antiestrogenic and antiandrugenic benzothiophenes
US4452813A (en) * 1981-05-22 1984-06-05 Taiho Pharmaceutical Company Limited Sulfonate derivatives, process for preparing same and antilipemic compositions containing the derivative
US4410520A (en) * 1981-11-09 1983-10-18 Ciba-Geigy Corporation 3-Amino-[1]-benzazepin-2-one-1-alkanoic acids
DK161312C (da) * 1982-03-11 1991-12-09 Pfizer Analogifremgangsmaade til fremstilling af 2-aminoalkoxymethyl-4-phenyl-6-methyl-1,4-dihydropyridin-3,5-dicarboxylsyreestere eller syreadditionssalte deraf samt phthalimidoderivater til anvendelse som udgangsmateriale ved fremgangsmaaden
GB2126576B (en) * 1982-06-25 1985-06-19 Farmos Group Limited Alkane and alkene derivatives
US4567175A (en) * 1983-06-03 1986-01-28 Tanabe Seiyaku Co., Ltd. 8-Chloro-1,5-benzothiazepine derivatives
CA1247547A (fr) * 1983-06-22 1988-12-28 Paul Hadvary Derives de leucine
FI844289L (fi) * 1984-01-21 1985-07-22 Hoechst Ag Nya polypeptider med -amylashaemmande verkan, foerfarande foer deras framstaellning, deras anvaendning och farmaceutiska preparat.
US4613610A (en) 1984-06-22 1986-09-23 Sandoz Pharmaceuticals Corp. Cholesterol biosynthesis inhibiting pyrazole analogs of mevalonolactone and its derivatives
ATE62906T1 (de) 1984-06-22 1991-05-15 Sandoz Ag Pyrazolanaloge von mevalonolakton und abkoemmlinge davon, verfahren zu deren herstellung und deren verwendung.
US4631286A (en) * 1984-10-25 1986-12-23 Hoechst-Roussel Pharmaceuticals Inc. 9-amino-1,2,3,4-tetrahydroacridin-1-ol and related compounds
US4634765A (en) * 1984-12-18 1987-01-06 Merrell Dow Pharmaceuticals Inc. Homodisaccharide hypoglycemic agents
US5061798A (en) * 1985-01-18 1991-10-29 Smith Kline & French Laboratories, Ltd. Benzyl pyridyl and pyridazinyl compounds
GB8501372D0 (en) * 1985-01-18 1985-02-20 Smith Kline French Lab Chemical compounds
IL74497A (en) * 1985-03-05 1990-02-09 Proterra Ag Pharmaceutical compositions containing phenyl carbamate derivatives and certain phenyl carbamate derivatives
GB8531071D0 (en) * 1985-12-17 1986-01-29 Boots Co Plc Therapeutic compound
US4663318A (en) * 1986-01-15 1987-05-05 Bonnie Davis Method of treating Alzheimer's disease
GB8608335D0 (en) * 1986-04-04 1986-05-08 Pfizer Ltd Pharmaceutically acceptable salts
US4681893A (en) * 1986-05-30 1987-07-21 Warner-Lambert Company Trans-6-[2-(3- or 4-carboxamido-substituted pyrrol-1-yl)alkyl]-4-hydroxypyran-2-one inhibitors of cholesterol synthesis
US4808621A (en) 1986-07-07 1989-02-28 Warner-Lambert Company Trans-6-[2-(N-heteroaryl-3,5-disubstituted)pyrazol-4-yl)-ethyl]- or ethenyl]tetrahydro-4-hydroxypyran-2-one inhibitors of cholesterol biosynthesis
US4957971A (en) * 1986-07-07 1990-09-18 Warner-Lambert Company Trans-6-(2-(N-heteroaryl-3,5-disubstituted)pyrazol-4-yl)-ethyl)-or ethenyl)tetrahydro-4-hydroxypyran-2-one inhibitors of cholesterol biosynthesis
DE3762617D1 (de) * 1986-09-11 1990-06-13 Nat Res Dev Tamoxifenderivate.
US4816456A (en) * 1986-10-01 1989-03-28 Summers William K Administration of monoamine acridines in cholinergic neuronal deficit states
FI95572C (fi) * 1987-06-22 1996-02-26 Eisai Co Ltd Menetelmä lääkeaineena käyttökelpoisen piperidiinijohdannaisten tai sen farmaseuttisen suolan valmistamiseksi
US5192772A (en) * 1987-12-09 1993-03-09 Nippon Shinyaku Co. Ltd. Therapeutic agents
NO177005C (no) * 1988-01-20 1995-07-05 Bayer Ag Analogifremgangsmåte for fremstilling av substituerte pyridiner, samt mellomprodukter til bruk ved fremstillingen
EP0344383A1 (fr) * 1988-06-02 1989-12-06 Merrell Dow Pharmaceuticals Inc. Inhibiteurs d'alpha-glucosidase
DE3836675A1 (de) * 1988-10-28 1990-05-03 Hoechst Ag Glykosidase-inhibitor salbostatin, verfahren zu seiner herstellung und seine verwendung
DE3918364A1 (de) 1989-06-06 1990-12-13 Hoechst Ag 3-desmethyl-2-methyl-mevalonsaeurederivate, verfahren zu ihrer herstellung, ihre verwendung als arzneimittel, sowie zwischenprodukte
US5185351A (en) * 1989-06-14 1993-02-09 Smithkline Beecham Corporation Imidazolyl-alkenoic acids useful as angiotensin II receptor antagonists
FI94339C (fi) * 1989-07-21 1995-08-25 Warner Lambert Co Menetelmä farmaseuttisesti käyttökelpoisen /R-(R*,R*)/-2-(4-fluorifenyyli)- , -dihydroksi-5-(1-metyylietyyli)-3-fenyyli-4-/(fenyyliamino)karbonyyli/-1H-pyrroli-1-heptaanihapon ja sen farmaseuttisesti hyväksyttävien suolojen valmistamiseksi
US5391571A (en) * 1989-11-15 1995-02-21 American Home Products Corporation Cholesterol ester hydrolase inhibitors
IT1237793B (it) * 1989-12-21 1993-06-17 Zambon Spa Composti attivi come inibitori dell'enzima hmg-coa reduttasi
US5196444A (en) * 1990-04-27 1993-03-23 Takeda Chemical Industries, Ltd. 1-(cyclohexyloxycarbonyloxy)ethyl 2-ethoxy-1-[[2'-(1H-tetrazol-5-yl)biphenyl-4-yl]methyl]benzimidazole-7-carboxylate and compositions and methods of pharmaceutical use thereof
US5504078A (en) * 1990-06-08 1996-04-02 Merrell Dow Pharmaceuticals Inc. α-glucosidase inhibitors
JPH054943A (ja) 1990-08-30 1993-01-14 Sagami Chem Res Center 光学活性β，δ−ジケト酸エステル及びその還元体
US5155120A (en) * 1991-01-14 1992-10-13 Pfizer Inc Method for treating congestive heart failure
US5274143A (en) * 1991-07-23 1993-12-28 Hoffmann-La Roche Inc. Process for the preparation of (R)-3-hexyl-5,6-dihydro-4-hydroxy-6-undecyl-2H-pyran-2-one and (R)-5,6-dihydro-6-undecyl-2H-pyran-2,4(3H)-dione
CA2098167C (fr) * 1992-06-24 2006-12-19 Dorothea Isler Aliments pour humains et animaux contenant un inhibiteur de la lipase
US5629295A (en) 1992-06-26 1997-05-13 Pfizer Inc. Steroidal glycosides for treating hypercholesterolemia
US5284971A (en) * 1992-07-16 1994-02-08 Syntex (U.S.A.) Inc. 4-(3-cyclohexyl-4-hydroxy or-methoxy phenylsulfonyl) 3,5 dibromo phenyl acetic thyromimetic cholesterol-lowering agents
DE69314718T2 (de) * 1992-07-21 1998-02-26 Ciba Geigy Ag Oxamidsäure-Derivate als hypocholesterämische Mittel
US5728704A (en) * 1992-09-28 1998-03-17 Pfizer Inc. Substituted pyridmidines for control of diabetic complications
DE4243279A1 (de) 1992-12-21 1994-06-23 Bayer Ag Substituierte Triole
TW381025B (en) * 1993-08-05 2000-02-01 Hoffmann La Roche Pharmaceutical composition containing a glucosidase inhibitor and a lipase inhibitor
US6756388B1 (en) 1993-10-12 2004-06-29 Pfizer Inc. Benzothiophenes and related compounds as estrogen agonists
US7501441B1 (en) * 1994-09-20 2009-03-10 Eli Lilly And Company Naphthyl compounds, intermediates, processes, compositions, and methods
KR970706242A (ko) 1994-10-04 1997-11-03 후지야마 아키라 우레아 유도체 및 ACAT-억제제로서 그의 용도(Urea derivatives and their use as ACAT-inhibitors)
JPH08143457A (ja) 1994-11-21 1996-06-04 Microbial Chem Res Found 酵素阻害剤および高脂血症抑制剤
US5510379A (en) * 1994-12-19 1996-04-23 Warner-Lambert Company Sulfonate ACAT inhibitors
US5552412A (en) * 1995-01-09 1996-09-03 Pfizer Inc 5-substitued-6-cyclic-5,6,7,8-tetrahydronaphthalen2-ol compounds which are useful for treating osteoporosis
US5510357A (en) * 1995-02-28 1996-04-23 Eli Lilly And Company Benzothiophene compounds as anti-estrogenic agents
GB9504066D0 (en) 1995-03-01 1995-04-19 Pharmacia Spa Phosphate derivatives of ureas and thioureas
FI974437A7 (fi) 1995-06-06 1997-12-05 Pfizer Substituoituja N-(indoli-2-karbonyyli)amideja ja johdannaisia glykogee nifosforylaasi-inhibiittoreina
DE69523182T2 (de) 1995-06-06 2002-02-07 Pfizer Substituierte n-(indol-2-carbonyl)-glycinamide und derivate als glycogen phosphorylase inhibitoren
WO1996040640A1 (fr) 1995-06-07 1996-12-19 Pfizer Inc. DERIVES DE BIPHENYL-2-ACIDE CARBOXYLIQUE-TETRAHYDRO-ISOQUINOLEINE-6-YL AMIDES, PREPARATION DE CES AMIDES ET UTILISATION EN TANT QU'INHIBITEURS DE LA PROTEINE DE TRANSFERT DE TRIGLYCERIDE MICROSOMAL ET/OU DE LA SECRETION D'APOLIPOPROTEINES B (Apo B)
GEP20002029B (en) * 1995-07-17 2000-04-10 Warner Lambert Company Us (54) Crystalline [R-(R*,R*,]–2-(4-Fluorophenyl)-Beta,Delta-Dihydroxy-5-(1-Methyl-Ethyl)-3-Phenyl–4-{Phenylamino) Carbonyl} - 1H - Pyrrole - 1 - Heptanoic Acid Hemi Calcium Salt (Atorvastatin)
JPH09173638A (ja) * 1995-12-25 1997-07-08 Hudson Soft Co Ltd 相対時間による派生シナリオ起動方法
TW513409B (en) * 1996-06-07 2002-12-11 Eisai Co Ltd Polymorphs of donepezil hydrochloride
WO1997046526A1 (fr) * 1996-06-07 1997-12-11 Eisai Co., Ltd. Polymorphes stables d'hydrochlorure de 1-benzyl-4-[(5,6-dimethoxy-1-indanon)-2-yl]methyl-piperidine), dit hydrochlorure de donepezil et procede pour leur production
TW506836B (en) * 1996-06-14 2002-10-21 Janssen Pharmaceutica Nv Fast-dissolving galanthamine hydrobromide tablet
JPH10310578A (ja) * 1996-11-13 1998-11-24 Yoshitomi Pharmaceut Ind Ltd ３−フェニルピラゾール化合物
EA001539B1 (ru) 1996-11-27 2001-04-23 Пфайзер Инк. Амиды, ингибирующие секрецию аполипопротеина в (аро в) и/или микросомного протеина переноса триглицеридов (мтр)
PE107899A1 (es) 1997-09-09 1999-11-17 Glaxo Group Ltd Derivados de pirrolopirrolona como inhibidores de elastasa leucocitaria
ES2218869T3 (es) * 1997-12-05 2004-11-16 Eisai Co., Ltd. Cristales polimorficos de donepezil y un proceso para produccion de dichos cristales.
EP1054860B1 (fr) 1997-12-19 2007-04-25 Pfizer Ireland Pharmaceuticals Procede de synthese de 1,3-diols
PA8471201A1 (es) * 1998-06-16 2000-09-29 Pfizer Prod Inc Combinaciones terapeuticas que comprenden un modulador del receptor de estrogenos selectivo y hormona paratiroidea
GT199900147A (es) * 1998-09-17 1999-09-06 1, 2, 3, 4- tetrahidroquinolinas 2-sustituidas 4-amino sustituidas.
US6197786B1 (en) * 1998-09-17 2001-03-06 Pfizer Inc 4-Carboxyamino-2-substituted-1,2,3,4-tetrahydroquinolines
ATE254928T1 (de) * 1999-03-31 2003-12-15 Eisai Co Ltd Stabilisierte zusammensetzung mit nootropen wirkstoffen
GB9914977D0 (en) * 1999-06-25 1999-08-25 Glaxo Group Ltd Chemical compounds
US6479552B2 (en) * 1999-09-23 2002-11-12 G.D. Searle & Co. Use of substituted N, N-disubstituted diamino compounds for inhibiting cholesteryl ester transfer protein activity
US6683113B2 (en) * 1999-09-23 2004-01-27 Pharmacia Corporation (R)-chiral halogenated substituted N,N-Bis-benzyl aminioalcohol compounds useful for inhibiting cholesteryl ester transfer protein activity
US20030171377A1 (en) * 2001-08-29 2003-09-11 Bigge Christopher Franklin Antidiabetic agents
US6875780B2 (en) * 2002-04-05 2005-04-05 Warner-Lambert Company Compounds that modulate PPAR activity and methods for their preparation
PT1567493E (pt) * 2002-11-26 2009-04-09 Pfizer Prod Inc Activadores de ppar
WO2004056359A1 (fr) * 2002-12-20 2004-07-08 Pfizer Products Inc. Formes posologiques comprenant un inhibiteur de la cetp et un inhibiteur de la hmg-coa reductase
US7250444B2 (en) * 2003-08-11 2007-07-31 Pfizer Inc. Pyrrole-based HMG-CoA reductase inhibitors
KR20060133013A (ko) * 2004-04-16 2006-12-22 워너-램버트 캄파니 엘엘씨 신규 이미다졸
AP2007003979A0 (en) * 2004-11-23 2007-06-30 Warner Lambert Co 7-(2h-pyrazol-3-yl)-3,5-dihyroxy-heptanoic acid derivatives as hmg co-a reductase inhibitors for thetreatment of lipidemia

Also Published As

Publication number Publication date
WO2006056845A1 (fr) 2006-06-01
DE602005016009D1 (de) 2009-09-24
ES2328384T3 (es) 2009-11-12
IL182569A0 (en) 2007-07-24
TW200626556A (en) 2006-08-01
KR20070084455A (ko) 2007-08-24
EP1819681A1 (fr) 2007-08-22
CA2590533C (fr) 2010-09-07
AP2007003979A0 (en) 2007-06-30
PA8653401A1 (es) 2006-09-08
MA30108B1 (fr) 2009-01-02
US20060111422A1 (en) 2006-05-25
PE20061057A1 (es) 2006-11-09
MX2007005137A (es) 2007-06-22
US7446121B2 (en) 2008-11-04
CR9102A (es) 2007-05-30
AU2005308575A1 (en) 2006-06-01
BRPI0518300A2 (pt) 2008-11-11
AR052244A1 (es) 2007-03-07
NL1030487A1 (nl) 2006-05-24
ATE439347T1 (de) 2009-08-15
JP2008520642A (ja) 2008-06-19
UY29220A1 (es) 2006-06-30
GT200500338A (es) 2006-06-22
EA200700875A1 (ru) 2007-12-28
US20090170852A1 (en) 2009-07-02
NL1030487C2 (nl) 2007-01-08
EP1819681B1 (fr) 2009-08-12
CA2590533A1 (fr) 2006-06-01

Similar Documents

Publication Publication Date Title
TNSN07202A1 (fr) Derives d'acide 7-(2h-pyrazole-3-yl)-3, 5-dihyroxy heptanoique servant d'inhibiteurs de hmg-co a reductase pour le traitement de la lipidemie
AP804A (en) APO-B-secretion/MTP inhibitory amides.
TW200519088A (en) Aryl or heteroaryl amide compounds
WO2005105732A8 (fr) Composes methylaryl- ou heteroarylamides substitues
FR2954317A1 (fr) Nouveaux derives phenoliques, et leur utilisation pharmaceutique ou cosmetique
DE69520502D1 (de) (azetidinyl-1-ylalkyl)lactame und zwischenprodukte als tachykinin antagonisten
MY123062A (en) Organometallic addition to ketones
CA2481461A1 (fr) Derives de n-[phenyl(piperidin-2-yl) methyl] benzamide, leur preparation et leur application en therapeutique
YU34796A (sh) Supstituisani n(indol-2-karbonil) гћві -alaninamid, njihovi derivati i farmaceutske smeše koje ih sadrže
GB2401606A (en) Pyranones useful as atm inhibitors
MA26983A1 (fr) Derives biaryliques de nicotinamide utiles comme inhibiteurs d'iso-enzymes pde4
ZA200607542B (en) MTP inhibiting aryl piperidines or piperazines substituted with 5-membered heterocycles
GB9900339D0 (en) Chemical compounds
TNSN06360A1 (fr) 4-phenylamino-quinazoline-6-yl-amides
CA2621040C (fr) Derives de 4-phenyl-6-substitue-pyrimidine-2-carbonitrile
HRP20090474T1 (hr) Postupak i intermedijeri za sintezu kaspofungina
HUP0203526A2 (hu) D4-antagonistákként alkalmazható tienoizoxazolil- és tienilpirazolil-fenoxi-helyettesített propilszármazékok, eljárás az előállításukra és ezeket tartalmazó gyógyszerkészítmények
DK1694641T3 (da) Prostaglandinsyntese
DE69612967D1 (en) Optisch aktive thiazolidinonderivate
RU2384573C2 (ru) Пиразол- и фенилпроизводные в качестве ингибиторов ppar
DK0854866T3 (da) Fremgangsmåde til fremstilling af 2-(pyrid-2-yloxymethyl)-phenylacetater som pesticidmellemprodukter
EP2516400A1 (fr) Dérivés phénoliques, et leur utilisation pharmaceutique ou cosmétique
HRP20020347B1 (en) Phenyl-and pyridyl-tetrahydro-pyridines having tnf inhibiting activity
AU6506894A (en) Perhydroisoindole derivatives, preparation thereof and pharmaceutical compositions containing same
Petrini et al. α-Amido sulfones from natural α-amino acids and their reaction with carbon nucleophiles